US Stocks
Kodiak Sciences Inc
Kodiak Sciences Inc

Kodiak Sciences Inc








Key Stats

Today Low/High
109.28 / 115.12
52 Week Low/High
$45.02 / $171.21
Market Cap

Company Details

Kodiak Sciences Inc. is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, Kodiak is focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Its ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, its bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and the company is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA.
Kodiak Sciences Inc
Health Technology

Discover more

Frequently Asked Questions

What is Kodiak Sciences Inc share price today

Can Indians buy Kodiak Sciences Inc shares?

How can I buy Kodiak Sciences Inc shares from India?

Can Fractional shares of Kodiak Sciences Inc be purchased?

What are the documents required to start investing in Kodiak Sciences Inc stocks?

We are a SEBI registered investement advisor